Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

4.555 +0.185 (+4.23%)
Streaming Delayed Price Updated: 3:18 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These 2 Stocks Are Making Big Monday Moves
Find out what's getting investors' attention in today's session. 
Via The Motley Fool
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
Patients had big decreases in LDL cholesterol. But there were some side effects. 
Via Investor's Business Daily
JOBY Stock Alert: Joby Aviation Scores New Tax Credit for Ohio Factory
Joby Aviation stock is getting a boost on Monday as investors in the company react to a new tax credit offer to build a factory in Ohio. 
Via InvestorPlace
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Verve Therapeutic Provides First Look At Gene-Editing Drug For Inherited High 'Bad' Cholesterol, Shares Fall
Verve Therapeutics Inc (NASDAQ: VERV) released the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b trial of VERVE-101 from the  
Via Benzinga
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Tracon Pharmaceuticals stock is falling on Monday as the company's shares give up their gains from an earnings rally on Friday. 
Via InvestorPlace
Why Is Verve Therapeutics (VERV) Stock Down 39% Today?
Verve Therapeutics stock is falling on Monday even after the company posted promising interim data from a Phase 1b clinical trial. 
Via InvestorPlace
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! 
Via InvestorPlace
Henry Schein, Verve Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mostly lower this morning on Monday, with the Nasdaq futures falling around 50 points this morning. 
Via Benzinga
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
1 Cathie Wood Stock to Buy Hand Over Fist Right Now
This next-generation gene therapy stock could be a big winner. 
Via The Motley Fool
2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher
Recent gains could be the start of a longer bull run. 
Via The Motley Fool
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology. 
Via The Motley Fool
Verve Stock Soars On $250 Million Eli Lilly Deal
Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Beam Therapeutics Stock Is Getting Bought Today
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's  
Via Benzinga
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Lilly Purchases Product Rights to Verve’s Lead Cardiovascular Programs from Beam Therapeutics 
From Verve Therapeutics
Via GlobeNewswire
With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?
It takes more than starting a clinical trial to make for a good investment. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS